LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Начало・Списък с акции・AnaptysBio Inc

AnaptysBio Inc

Затворен

СекторЗдравеопазване

64.74 4.89

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

60.65

Максимум

66.45

Ключови измерители
By Trading Economics
Приходи	35M 50M
Продажби	32M 108M
Марж на печалбата	45.833
Служители	104
EBITDA	29M 68M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+31.54% upside

Дивиденти
By Dow Jones
Следващи печалби	1.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	180M 1.7B
Предишно отваряне	59.85
Предишно затваряне	64.74

Настроения в новините

By Acuity

44%

56%

136 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

19.25 / 21.135 Подкрепа & съпротива

AnaptysBio Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.03.2026 г., 20:38 ч. UTC

Печалби

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10.03.2026 г., 23:06 ч. UTC

Печалби

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10.03.2026 г., 22:51 ч. UTC

Значими събития в новините

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10.03.2026 г., 21:39 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10.03.2026 г., 21:21 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10.03.2026 г., 21:15 ч. UTC

Печалби

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10.03.2026 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10.03.2026 г., 21:14 ч. UTC

Печалби

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10.03.2026 г., 21:13 ч. UTC

Печалби

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q Rev $597.3M >FNV

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q EPS $1.90

10.03.2026 г., 20:57 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

10.03.2026 г., 20:44 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10.03.2026 г., 20:23 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:16 ч. UTC

Печалби

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10.03.2026 г., 20:13 ч. UTC

Печалби

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10.03.2026 г., 20:12 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

AnaptysBio Inc Прогноза

Ценова цел

By TipRanks

31.54% нагоре

12-месечна прогноза

Среден 81.57 USD 31.54%

Висок 140 USD

Нисък 50 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за AnaptysBio Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на AnaptysBio Inc през последните 3 месеца.

Техническа оценка

By Trading Central

19.25 / 21.135Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

136 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.